Seattle Genetics (SGEN) Submits sBLA to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma
Tweet Send to a Friend
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
